Dara-RVd Reduces Risk of Progression or Death in Transplant-Eligible NDMM
August 28th 2022The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.
Read More
Carfilzomib Plus Lenalidomide/Dexamethasone After Transplant Extends PFS Over Lenalidomide in MM
August 26th 2022Data presented at the 19th International Myeloma Society Annual Meeting show that carfilzomib plus lenalidomide and dexamethasone after transplant prolongs progression-free survival compared with lenalidomide alone in patients with myeloma.
Read More
Daratumumab Plus Lenalidomide/Dexamethasone Prolong OS When Administered Long-Term in Myeloma
August 26th 2022Patients with treatment-naive myeloma treated with humanized IgGx CD38-targeted monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone for at least 18 months had a overall survival benefit in the phase 3 MAIA study.
Read More
Isa-Kd Maintains Long-Term PFS Benefit in Relapsed Multiple Myeloma
August 26th 2022Updated analysis of the IKEMA trial showed the combination of isatuximab, carfilzomib, and dexamethasone to elicit superior progression-free survival vs carfilzomib and dexamethasone alone in patients with multiple myeloma.
Read More
Lenalidomide Triplet plus ASCT Significantly Improves PFS in Multiple Myeloma
August 26th 2022Findings from the phase 3 DETERMINATION trial show lenalidomide plus bortezomib, dexamethasone, and autologous stem cell transplantation to improve progression-free survival in patients with multiple myeloma.
Read More
STOMP Trial Shows High Activity in R/R Multiple Myeloma With Selinexor Regimen
September 17th 2019Selinexor plus lenalidomide and dexamethasone, an all-oral triplet, was found to be highly active in patients with relapsed or refractory multiple myeloma, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop. The regimen is also well tolerated and especially active in patients who did not receive lenalidomide prior to the trial.
Read More
The combination of melflufen and dexamethasone showed antitumor activity in patients with relapsed or refractory multiple myeloma, both in those with and those without extramedullary disease, according to data from the phase II HORIZON study presented at the 17th International Myeloma Workshop.
Read More
Daratumumab Plus VRd Improved Depth of Response in Transplant-Eligible, Newly Diagnosed Myeloma
September 15th 2019The GRIFFIN study showed that the addition of daratumumab to bortezomib, lenalidomide, and dexamethasone, improved stringent complete response in transplant-eligible patients with newly diagnosed multiple myeloma without affecting stem cell mobilization or hematopoietic reconstitution, according to results presented at the 17th International Myeloma Workshop.
Read More
Antitumor Activity Observed With Iberdomide in Heavily Pretreated Myeloma
September 15th 2019Novel agent iberdomide in combination with dexamethasone was safe and demonstrated antitumor activity in patients with relapsed/refractory multiple myeloma who were heavily pretreated, according to findings from a phase Ib/IIa trial presented at the 17th International Myeloma Workshop.
Read More
Promising PFS Shown With Isatuximab Triplet in High-Risk Multiple Myeloma
September 15th 2019In an interview with <em>Targeted Oncology</em> during the 17th IMW Scientific Program, Simon J. Harrison, MBBS, PhD, discussed the subgroup findings from the ICARIA-MM study in relapsed/refractory multiple myeloma.
Read More
Melflufen Plus Dexamethasone Safe and Effective For R/R Multiple Myeloma
September 15th 2019Paul G. Richardson, MD, clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard School of Medicine, discusses the interesting safety and efficacy profiles of the HORIZON trial.
Read More
Efficacy Seen With Isatuximab Regimen in High-Risk Multiple Myeloma
September 14th 2019The addition of isatuximab to carfilzomib, lenalidomide, and dexamethasone led to a response rate in all 10 patients included in a safety run-in cohort of the phase II, multicenter GMMG-CONCEPT trial.
Read More
Daratumumab-Based Quadruplet Demonstrates Efficacy in High-Risk Myeloma Subgroups
September 14th 2019Daratumumab in combination with bortezomib, thalidomide, and dexamethasone demonstrated benefit compared with VTd alone in subgroup analyses of patients with high-risk multiple myeloma from the phase III CASSIOPEIA trial.
Read More